B-hCD3EDG/HLA-A2.1 mice

C57BL/6-Cd3etm1(CD3E)Bcgen Cd3dtm1(CD3D)Bcgen Cd3gtm1(CD3G)Bcgen B2mtm2(B2M/HLA-A2.1/H2-D)Bcgen/Bcgen • 112756

B-hCD3EDG/HLA-A2.1 mice

Product nameB-hCD3EDG/HLA-A2.1 mice
Catalog number112756
Strain nameC57BL/6-Cd3etm1(CD3E)Bcgen Cd3dtm1(CD3D)Bcgen Cd3gtm1(CD3G)Bcgen B2mtm2(B2M/HLA-A2.1/H2-D)Bcgen/Bcgen
Strain backgroundC57BL/6
NCBI gene ID916,915,917,3105 (Human)
AliasesIMD18, T3E, TCRE; CD3-DELTA, IMD19, T3D; CD3-GAMMA, IMD17, T3G; HLAA

このページで

  • Description
  • Targeting strategy
  • Phenotypic analysis

ポスター

すべて表示

    出版物

      Description
      • Background: CD3 consists of four protein chains (CD3E, CD3D, CD3G and CD3Z), which are important biological markers on the T cell membrane. CD3 can form a TCR/CD3 complex with the T cell receptor, participating in the regulation of T cell antigen recognition, signal transduction and T cell development. CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. The B2M encodes a serum protein found in association with the major histocompatibility complex (MHC) class I heavy chain on the surface of nearly all nucleated cells. The protein has a predominantly beta-pleated sheet structure that can form amyloid fibrils in some pathological conditions. HLA-A belongs to the HLA class I heavy chain paralogues. The heavy chain is anchored in the membrane. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen so that they can be recognized by cytotoxic T cells. They are expressed in nearly all cells.
      • Targeting strategy: B-hCD3EDG/HLA-A2.1 mice were obtained by mating B-hCD3EDG mice(110039) and B-HLA-A2.1 mice(110110). In B-hCD3EDG/HLA-A2.1 mice, chimeric human CD3EDG was expressed, while mouse Cd3edg were knocked out. The B2M gene (Exon1 to Exon3) of mouse were replaced by the sequence encompassing the human B2M CDS and HLA-A*0201 gene that included leader sequence, α1 and α2 domains ligated to a fragment of the murine H-2Db gene containing the α3, transmembrane and cytoplasmic domains.
      • Protein expression: Mouse CD3E was only detectable on T cells from spleen of in wild-type C57BL/6 mice (+/+). Human CD3E was detectable in B-hCD3EDG/HLA-A2.1 mice (CD3EDGH/H; HLA-A2.1H/+) and B-hCD3EDG/HLA-A2.1 mice (CD3EDGH/H; HLA-A2.1H/H) , but not in wild-type C57BL/6 mice (+/+). Mouse H-2Db was detectable in spleen of wild-type C57BL/6 mice (+/+) and B-hCD3EDG/HLA-A2.1 (CD3EDGH/H; HLA-A2.1H/+). Human HLA-A2.1 was detectable in B-hCD3EDG/HLA-A2.1 (CD3EDGH/H; HLA-A2.1H/+) and B-hCD3EDG/HLA-A2.1 (CD3EDGH/H; HLA-A2.1H/H), but not in wild-type C57BL/6 mice (+/+).
      • Leukocytes cell subpopulation analysis:Compared with C57BL/6 mice, the frequencies CD4+ T cells and CD8+ T cells changed in B-hCD3EDG/HLA-A2.1 mice, especially the frequency of CD8+ T cells in B-hCD3EDG/HLA-A2.1 mice (CD3EDGH/H; HLA-A2.1H/H)  decreased significantly. No significant decrease in the frequency of CD8+ T cells was previously observed in B-hCD3EDG mice, so we speculated that the introduction of hB2M-HLA-A2.1-H-2D instead of mouse counterparts may affect the development of CD8+T cells in spleen, lymph node and blood.
      • Application: This product is used for the pharmacological and safety evaluation of antibodies in oncology.
      Targeting strategy

      Gene targeting strategy for B-hCD3EDG/HLA-A2.1 mice. The chimeric human CD3EDG was expressed, while mouse Cd3edg were knocked out. The B2M gene (Exon1 to Exon3) of mouse were replaced by the sequence encompassing the human B2M CDS and HLA-A*0201 gene that included leader sequence, α1 and α2 domains ligated to a fragment of the murine H-2Db gene containing the α3, transmembrane and cytoplasmic domains.

      Protein expression analysis in spleen

      Strain specific CD3E expression analysis in wild-type C57BL/6 mice and humanized B-hCD3EDG/HLA-A2.1 mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice and B-hCD3EDG/HLA-A2.1 mice, and analyzed by flow cytometry. Mouse CD3E was only detectable in wild-type C57BL/6 mice (+/+). Human CD3E was detectable in B-hCD3EDG/HLA-A2.1 mice (CD3EDGH/H; HLA-A2.1H/+) and B-hCD3EDG/HLA-A2.1 mice (CD3EDGH/H; HLA-A2.1H/H) , but not in wild-type C57BL/6 mice (+/+).

      Strain specific HLA expression analysis in wild-type C57BL/6 mice and humanized B-hCD3EDG/HLA-A2.1 mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice and B-hCD3EDG/HLA-A2.1 mice, and analyzed by flow cytometry. Mouse H-2Db was detectable in wild-type C57BL/6 mice (+/+) and B-hCD3EDG/HLA-A2.1 (CD3EDGH/H; HLA-A2.1H/+). Human HLA-A2.1 was detectable in B-hCD3EDG/HLA-A2.1 (CD3EDGH/H; HLA-A2.1H/+) and B-hCD3EDG/HLA-A2.1 (CD3EDGH/H; HLA-A2.1H/H), but not in wild-type C57BL/6 mice (+/+).

      Frequency of leukocyte subpopulations in spleen

      Frequency of leukocyte subpopulations in spleen by flow cytometry. Splenocytes were isolated from wild-type C57BL/6 mice and homozygous B-hCD3EDG/HLA-A2.1 mice (n=3, 7-week-old). A. Flow cytometry analysis of the splenocytes was performed to assess the frequency of leukocyte subpopulations. B. Frequency of T cell subpopulations. Frequencies of T cells, B cells, NK cells, dendritic cells, neutrophils, monocytes and macrophages in B-hCD3EDG/HLA-A2.1 mice were similar to those in the C57BL/6 mice. Compared with C57BL/6 mice, the frequency of  CD4+ T cells and CD8+ T cells changed in B-hCD3EDG/HLA-A2.1 mice, especially the frequency of CD8+ T cells in B-hCD3EDG/HLA-A2.1 mice (CD3EDGH/H; HLA-A2.1H/H)  decreased significantly. No significant decrease in the frequency of CD8+ T cells was previously observed in B-hCD3EDG mice, so we speculated that the introduction of hB2M-HLA-A2.1-H-2D instead of mouse counterparts may affect the development of CD8+T cells in spleen. Values are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

      Frequency of leukocyte subpopulations in blood

      Frequency of leukocyte subpopulations in blood by flow cytometry. Blood cells were isolated from wild-type C57BL/6 mice and homozygous B-hCD3EDG/HLA-A2.1 mice (n=3, 7-week-old). A. Flow cytometry analysis of the blood leukocytes was performed to assess the frequency of leukocyte subpopulations. B. Frequency of T cell subpopulations. Frequencies of NK cells, dendritic cells, neutrophils, monocytes and macrophages in B-hCD3EDG/HLA-A2.1 mice were similar to those in the C57BL/6 mice. Compared with C57BL/6 mice, the frequency of  CD4+ T cells and CD8+ T cells changed in B-hCD3EDG/HLA-A2.1 mice, especially the frequency of CD8+ T cells in B-hCD3EDG/HLA-A2.1 mice (CD3EDGH/H; HLA-A2.1H/H)  decreased significantly. No significant decrease in the frequency of CD8+ T cells was previously observed in B-hCD3EDG mice, so we speculated that the introduction of hB2M-HLA-A2.1-H-2D instead of mouse counterparts may affect the development of CD8+T cells in blood. Values are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

      Frequency of leukocyte subpopulations in lymph node

      Frequency of leukocyte subpopulations in lymph node by flow cytometry. Lymph nodes were isolated from wild-type C57BL/6 mice and homozygous B-hCD3EDG/HLA-A2.1 mice (n=3, 7-week-old). A. Flow cytometry analysis of the leukocytes was performed to assess the frequency of leukocyte subpopulations. B. Frequency of T cell subpopulations. Frequencies of T cells, B cells and NK cells in B-hCD3EDG/HLA-A2.1 mice were similar to those in the C57BL/6 mice. Compared with C57BL/6 mice, the frequency of  CD4+ T cells and CD8+ T cells changed in B-hCD3EDG/HLA-A2.1 mice, especially the proportion of CD8+ T cells in B-hCD3EDG/HLA-A2.1 mice (CD3EDGH/H; HLA-A2.1H/H) decreased significantly. No significant decrease in the frequency of CD8+ T cells was previously observed in B-hCD3EDG mice, so we speculated that the introduction of hB2M-HLA-A2.1-H-2D instead of mouse counterparts may affect the development of CD8+T cells in lymph node. Values are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

      * When publishing results obtained using this animal model, please acknowledge the source as follows: The animal model [B-hCD3EDG/HLA-A2.1 mice] (Cat# 112756) was purchased from Biocytogen.